Introduction
Electroconvulsive Therapy (ECT) is a very effective treatment for drug-resistant major depressive disorder and bipolar disorder, as well as acute resistant schizophrenia [1] . Multiple mechanisms modifying the brain's macro-and micro-environment have been proposed to support the therapeutic effect of ECT, including changes in neurotransmission, gene expression, functional connectivity, or even modifications to the neuroendocrine and immune systems [2] . These theories of how ECT works were mainly developed based on results obtained from electroconvulsive stimulation (ECS), the animal equivalent of ECT [3] . However, much of the data remains inconclusive as the vast majority of studies were performed with "naive" animals in which the biological effects induced by ECS might not be due to relief of underlying disease and did not correlate with behavioral improvements over time. Notably, some analyses of the effect of ECS on animal models developed to assess antidepressant activity used acutely-induced behavioral deficits or animal models developed to study stress and anxiety such as the CORT or Learned Helplessness rat models [4] [5] [6] [7] .
Extensive literature mining clearly shows that we still lack evidence from animal models exhibiting hallmark constitutive behavioral and biological characteristics of severe psychiatric disorders. In this context, we developed a translational approach with MAP6 KO mice (also known as STOP KO mice). These animals constitutively exhibit behavioral and biological features relevant to some aspects of major depressive disorder, such as social withdrawal [8] [9] [10] , anhedonia [11] , and reduced motivation [11] [12] [13] . Biological defects include diminished neurogenesis [13] , impaired synaptic plasticity in the hippocampus [10, 14] , and abnormal excitatory and monoaminergic transmissions [10, 13, 15, 16] .
The neurotrophic theory for ECT/ECS suggests that its effect is linked to its capacity to stimulate hippocampal neurogenesis, synaptic plasticity and growth factor expression [17] [18] [19] [20] [21] . With regard to neurogenesis, current evidence clearly indicates that repeated ECS increases hippocampal progenitor proliferation [17] [18] [19] 22] , but these new progenitors have yet to be directly linked to behavioral improvement. Here, we scheduled ECS treatment to mimic clinical ECT protocols in M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 5 humans, our results demonstrate that its beneficial effect on behavioral traits was linked to increased integration of neurons present before ECS treatment in MAP6 KO mice. In addition, ECS treatment induced an overall increase in neuronal connectivity. Finally, we demonstrate that the behavioral and biological effects of ECS can be sustained for several weeks by applying a continuation ECS protocol following the initial ECS treatment.
Materials & Methods

Protocol design
Initially, the effect of ECS treatment on the behavioral deficits observed in MAP6 KO mice was assayed (Fig1). Next, the biological effects of ECS treatment on neuronal progenitor proliferation and neurotrophic factors levels (Fig2) and on new-born neurons integration and connectivity (Fig3) were investigated. Subsequently, the relationship between behavioral improvement and survival of newborn neurons was investigated (Fig 4) , and finally the impact of a consolidation protocol on these two last parameters was assayed (Fig 5) .
Animals
MAP6 KO model:
Homogeneous inbred C57BL6/129SvPas-F1 MAP6 KO and MAP6 KO/Thy1-eYFP-H mice were obtained as previously described [23] . All experiments were performed using 2-5-month-old males and mice were carefully matched for age across treatment groups. Researchers performing all procedures, apart from ECS treatment, were blinded to the animal's treatment group.
The study protocol (APAFIS number 8303-2016060110523424v4) was approved by the local animal welfare committee (Comité Local GIN, C2EA-04) and complied with EU guidelines (directive 2010/63/EU). Every precaution was taken to minimize stress and the number of animals used in each experiment.
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CORT model: Corticosterone (Sigma Aldrich) was dissolved in 0.45% hydroxypropyl-β-cyclodextrin (Sigma Aldrich). CORT (35 µg/ml/d) was administered to C57Bl6 male mice ad libitum via the drinking water as described in [21] .
Electroconvulsive Seizures (ECS)
Initial ECS treatment consisted of 10 ECS sessions delivered using an Ugo Basile generator (model 57800) over a 12-day period (D1-5 and D8-12). Mice were anesthetized using isoflurane prior to ECS delivery via bilateral ear-clip electrodes. Titration experiments were performed with MAP6 KO mice to determine the seizure threshold (seizures lasting more than 10 s). The duration of stimulation was then doubled to obtain the following parameters: frequency 120 Hz, pulse width 0.5 ms, total stimulation duration 2 s, current 20 mA. Continuation ECS treatment consisted of 10 ECS sessions over a 5-week period (2 ECS sessions/week) after the initial ECS treatment. Shamtreated animals were handled similarly, but no current was delivered.
Behavioral tests
Forced swimming test (FST)
The FST [24] was performed in a vertical glass cylinder (h=30 cm; d=15 cm) containing 20 cm of water maintained at 24+/-1 °C. The total duration of immobility and climbing were recorded for 6 min. An animal was considered immobile when it floated passively, performing only slow movements to keep its head above water. Climbing was defined as upward-directed movements of the forepaws along the side of the container.
Novelty suppressed feeding test (NSF)
The NSF test is an anxiety-based conflict test where the motivation to eat competes with fear of a brightly lit area [25, 26] . The NSF test was performed for 15 min. Briefly, animals had no access to food in their home cage for 20 h prior to performing the test, for the test, a single food pellet was placed on a brightly-lit white paper platform placed in the center of a plastic box (L37 x l57 x h20 M A N U S C R I P T
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7 cm) where the floor was covered with approximately 2 cm of bedding. The animal was placed in a corner of the box and the latency to eat was recorded.
Open field test
Mice were placed in an open field (50 X 50 cm) and motor activity was automatically recorded for 20 min.
BrdU, EdU and DCX staining
To study neuronal proliferation, mice were injected with 5-bromo-2'-deoxyuridine (BrdU) (100 mg/kg) on D3 following ECS treatment (2 injections spaced 6 h apart) and on D4 (1 injection).
Animals were sacrificed 2 h after the final BrdU injection. To study post-ECS cell survival, mice were injected with BrdU or EdU (5-ethynyl-2'-deoxyuridine) (50 mg/kg) once daily for 4 days, 2 weeks before starting the ECS treatment. To study cell survival after the continuation protocol, mice were injected with EdU (50 mg/kg) once daily for 4 days, 2 weeks before starting the initial ECS treatment, and with BrdU (50 mg/kg) once daily for the last 4 days of initial treatment. Mice were sacrificed by transcardial perfusion with 4% paraformaldehyde, and brains were post-fixed for 15 h cryoprotected in sucrose, before slicing into coronal free-floating sections (40 µm).
Immunochemistry to reveal BrdU and DCX was performed as previously described [13] with antiBrdU (1:2000 dilution of rat AbC117-7513, Abcys) and anti-DCX antibodies (guinea-pig at 1:10000; AB2253, Millipore). For EdU staining, free-floating sections permeabilized for 90 min (in PBS 0.2% gelatin, 0.5% Triton X100, 0.1% saponin). EdU-labeled cells were visualized following a 15-min click reaction (5% Tris 2 M pH 7, 80.9% H 2 O, 4% CuSO 4 100 mM, 0.1% Cyanine 3 Azide 1 mM, 10% Ascorbic acid 1 M). Sections were viewed by microscopy (Zeiss axioskop). BrdU-or EdU-labeled nuclei were counted within the dentate gyrus every 4 sections throughout the rostrocaudal extent of the hippocampus from bregma -1.34 to -3.38. As anti-BrdU antibodies also 
BDNF assays
Mice were euthanized by cervical dislocation. Bilateral hippocampi were harvested and rapidly dissected on ice, frozen in liquid nitrogen and stored at -80°C.
For real-time RT-qPCR, RNA was isolated using Mini RNeasy kit (Qiagen), quantified based on absorbance at 260 nm (NanoPhotometer, IMPLEN), and 1 µg RNA was converted to cDNA using the QuantiTect Reverse Transcription kit (Qiagen) according to the manufacturer's instructions.
PCR was performed on a LightCycler 480 SYBR Green I Master (Roche Applied Science) with 1 µL cDNA and the following oligonucleotides (QuantiTect Primer Assays, Qiagen): BDNF (QT00375998) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, QT001199633).
Quantitative RT-PCR was performed with a Roche LC480 Light Cycler (Roche Applied Science) according to the manufacturer's instructions. Relative mRNA levels were calculated using LC480 software, after normalizing for GAPDH levels. PCR was performed in triplicate.
BDNF proteins were analyzed in brain homogenate by ELISA (BDNF E max ImmunoAssay System, Promega) according to the manufacturer's protocol. BDNF levels were normalized relative to total protein content, as determined by BCA assay (Thermo Scientific).
Analyzing newborn neurons using retroviruses
Virus injection
The viral solution (10 8 pfu/mL) was prepared with the retroviral vector (pCAG-IRES-GFP) and HEK 293T as a packaging cell line. Viral particles were collected by ultra-speed centrifugation.
Four weeks before the end of ECS treatment, mice were anesthetized with chloral hydrate solution (400 mg/kg) and stereotaxic surgery was performed to deliver the virus solution (500 nL) to the dentate gyrus in the hippocampus at a rate of 0.4 µL/min. The injection site for adult mice was determined based on previous studies, using the position relative to the bregma as reference:
anteroposterior: -2.1 mm; lateral: +/-1.42 mm; ventral: -1.9 mm (from skull).
GFP immunolabeling
GFP immunolabeling was performed on free-floating coronal sections after blocking and permeabilization for 1 h with PBS, 0.1% Tween 20, 0.5% Triton X100, and 5% normal goat serum.
Sections were incubated overnight at 4 °C with primary rabbit anti-GFP antibody (1:1000 dilution of #11122, Invitrogen). After washing with PBS, 0.1% Tween 20, sections were incubated for 1 h with Alexa488-coupled secondary anti-rabbit antibody (1:1000; Jackson Laboratories).
Sholl analysis
Image stacks showing individual neurons were acquired at 20x magnification (Zeiss LSM 710 confocal microscope). Image stacks were enhanced with a DoG filter and segmented. Single neurons were recovered using the "Find connected region" Fiji software plugin [27] . The resulting stack was used for Sholl analysis [28] with a starting radius and step size of 5 µm.
Spine analysis
Stacks of serial optical sections were produced for each neuron (at 63x magnification) and 3D
reconstructions of dendritic arbors and spines were generated (NeuronStudio software version 0.9.92) to measure spine density [29] . Images were acquired on the distal part of the dendritic arbors of GFP-labeled newborn neurons.
[12, 13]Dendritic spine quantification
Spine analysis was performed in the motor cortex of the MAP6 KO Thy1-eYFP-H mouse line.
Some neurons in this area express the YFP transgene, allowing the detection of spines for individual neurons. Stacks of serial optical sections were produced for each neuron [29] and spine density was quantified using NeuronStudio software.
Statistical analysis
Statistical analyses were performed using Prism 5.0 software (GraphPad Software) or XLSTAT 2016 (Microsoft). Bilateral non-parametric Mann-Whitney U tests were used to compare WT vs.
KO; KO Sham vs. KO ECS comparisons were performed using unilateral Mann-Whitney U tests
since only improvement of the condition was sought. Choice of this type of test was justified based on previous and present results obtained with these MAP6 KO versus wild type animals [12, 13] .
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
Results
MAP6 KO mice exhibit several behavioral and biological defects reminiscent of major depressive episodes, including social withdrawal [9, 10, 14] , anhedonia and reduced motivation [11] [12] [13] .
Biological defects include diminished neurogenesis [13] , impaired plasticity [10, 14] and abnormal excitatory and monoaminergic transmissions [10, 13, 15, 16] . Here, we analyzed the impact of 10 sessions of ECS treatment over 2 weeks on MAP6 KO mice, in terms of behavioral, anatomic and physiological parameters ( Figure 1A ).
ECS treatment improves the depressive/anxiety-like status of MAP6 KO mice
The effect of ECS treatment on despair behavior in MAP6 KO mice was analyzed using the FST, a Figure 1B ).
In parallel, we monitored the depressive/anxiety-like status of MAP6 KO mice using the NSF test, where the animal's motivation to eat competes with the aversive signal of bright illumination; latency to eat is measured. MAP6 KO mice displayed a significant higher latency than WT mice (235 ± 19 s for WT mice (n=7) vs. 171 ± 14.5 s for MAP6 KO mice (n=9), unilateral MannWhitney test, p= 0.0131, Figure 1C ). Interestingly, at D4 after the end of the treatment, the latency to eat for ECS-treated MAP6 KO mice was 226 ± 51.5 s, whereas sham-treated MAP6 KO mice had a latency of 413 ± 57 s (for Sham-and ECS-treated mice (n= 13); unilateral Mann-Whitney test, Figure 1D ). The difference between the values observed after sham treatment (413 ± 57 s) or without treatment (235 ± 19 s) was probably due to stress induced by handling animals over the two weeks of the protocol.
We checked the effect of ECS on locomotor activity, since it could influence performance in FST and NSF tests. Locomotor activity was monitored in an open-field on D3 after ECS treatment for 20 minutes; no significant difference between Sham-and ECS-treated mice was observed (8514±1045 cm for Sham-(n=8) vs. 7605±818 cm for ECS treated mice (n=10)).
Altogether, these behavioral tests clearly demonstrated a considerable beneficial effect of ECS treatment on constitutive depressive/anxiety-like behavior in MAP6 KO mice.
ECS treatment does not alter proteomic profile
ECS treatment has been suggested to activate specific neuronal pathways. We therefore analyzed the proteomic content of total brain and hippocampal samples from MAP6 KO mice treated by ECS or sham protocols (Supplementary data). The results did not confirm this hypothesis: among more than 2,000 different proteins identified, only three were significantly differentially expressed (2-fold change) between ECS and sham conditions (Supplementary data). Thus, ECS treatment induced no major detectable changes in the brain proteome and no specific biological pathway is activated/inhibited following ECS treatment. However, minor modifications to expression levels for a large number of proteins may nevertheless significantly alter brain activity. Based on these results, and in line with the available evidence, we therefore focused our study on the neurogenic effects of ECT.
ECS treatment enhances proliferation of adult hippocampal neuronal progenitors
ECS treatment has been linked to enhanced proliferation of neuronal progenitors in the hippocampus in both rodent and non-human primate models [17, 18, 22] . We therefore analyzed progenitor proliferation in MAP6 KO mice after ECS/sham treatment.
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BrdU was used to label proliferating cells (Figure 2A ). The number of BrdU-positive cells in the hippocampus was measured at D4 after completing treatment ( Figure 2B ). ECS-treated mice had 46% more BrdU-positive cells than sham-treated mice (1267 ± 143 for Sham (n=4) vs. 2150 ± 272
for ECS-treated mice (n=5), unilateral Mann-Whitney test, p= 0.0278; Figure 2C ). Subsequently, we examined whether ECS also triggered progenitor differentiation to form neuroblasts/immature neurons. DCX immunolabeling was performed at D4 after completing treatment to identify neuroblasts/immature neurons ( Figure 2D ). ECS treatment resulted in a 127% increase in DCXpositive hippocampal cells compared to sham treatment (5080 ± 753 for Sham (n=8) vs. 11539 ± 776 for ECS-treated mice (n=8), unilateral Mann-Whitney test, p < 0.0001; Figure 2E ). These results indicate that ECS enhances the proliferation of hippocampal progenitors and triggers their differentiation to form neuroblasts/immature neurons. Figure 2G ). Thus, in MAP6 KO mice, ECS enhances the expression of the trophic factor, BDNF.
ECS treatment increases BDNF expression
ECS treatment enhances survival of hippocampal neurons born before treatment and favors their maturation and integration
The proliferation of neuronal progenitors induced by ECS treatment cannot account for the rapid behavioral improvement observed from D1 after treatment ( Figure 1B, 1D To assay if enhanced survival of hippocampal neurons might be a general consequence of ECS treatment, we analyzed neuron survival in cortisone (CORT)-induced depression, a neuroendocrine depression model known to positively respond to ECS treatment [21] . CORT was administered to male wild-type mice by addition to drinking water. Proliferating cells were labeled with EdU, 4
weeks before the end of ECS treatment (timeline shown Figure 3C ). Following treatment, we determined the number of hippocampal EdU-positive cells, corresponding to the set of newborn cells which had reached maturity. ECS-treated CORT mice had 125% more EdU-positive cells in their hippocampus than sham-treated mice (293 ± 13 for Sham (n=10) vs. 661 ± 34 for ECS-treated mice (n=10), unilateral Mann-Whitney test, p < 0.0001,; Figure 3D ). ECS therefore strongly enhances the survival and integration of spontaneously produced newborn neurons in the hippocampus of CORT treated mice, similar to its effect in MAP6 KO mice.
he maturation and integration status of these newborn neurons was investigated in MAP6 KO mice, using a retrovirus (pCAG-IRES-GFP virus) to identify cells in the dentate gyrus; the timeline was
as shown in Figure 3A (virus injection replacing BrdU injection). GFP was visualized on D4 after ECS treatment, i.e., four weeks after virus injection, to allow morphological identification of newborn neurons, including their dendritic organization and complexity ( Figure 3E ). Sholl analysis of neuronal dendritic arborization indicated increased dendritic complexity in ECS-treated animals, with a 30% increase in the number of dendritic intersections (2.58 ± 0.12 for Sham (n=11) vs. 3.38 ± 0.2 for ECS-treated mice (n=8), unilateral Mann-Whitney test, p= 0.0022, Figure 3F ). Dendritic spine density was also increased (+22%) in the distal part of newborn neurons after ECS treatment Mann-Whitney test, p=0.0284, Figure 3G ). In addition, we examined the three main morphologies for spines: thin, stubby and mushroom spines ( Figure 3H ). No difference in density was observed for thin and stubby spines between treatments, however the density of mature mushroom-like spines was significantly higher after ECS treatment compared to sham treatment (0.07±0.01 for Sham Figure 3H ). These results suggest that ECS treatment boosts dendritic arborization and mature spine density, enhancing the connectivity of neurons already present before ECS treatment.
Reduced dendritic spine density has been reported in animal models of depression [31, 32] . We also observed reduced spine density (compared to WT mice) in MAP6 KO mice cross-bred with Thy1-eYFP-H transgenic mice to visualize dendritic spines in vivo in layer 5 cortical neurons (Peris 2018, submitted). Using these animals, we assessed how ECS treatment affects spine density in mature cortical neurons ( Figure 3I ). ECS treatment increased spine density by 29% compared to sham treatment (1.07±0.06 for Sham (n=17) vs. 1.36±0.09 for ECS-treated mice (n=26) spines/µm, unilateral Mann-Whitney test, p=0.0303, Figure 3J ), indicating that ECS treatment induces a general increase in dendritic spine density.
Behavioral improvement of MAP6 KO mice was associated with survival of newborn neurons
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As our animal model exhibited constitutive symptoms which were alleviated just after ECS treatment, we evaluated long-term effects including possible relapse, as observed in humans treated by ECT. The NSF test was applied at several time points following treatment ( Figure 4A Figure 4B ). In contrast, at D33 post-treatment, the differences between the two groups were no longer significant ( Figure   4B ). Thus, ECS treatment alleviated the depressive/anxiety-like state of MAP6 KO mice for at least 17 days after treatment.
We next examined the survival of newborn neurons over time ( Figure 4A ). The number of surviving newborn neurons was significantly increased in ECS-treated mice compared to sham- We analyzed the relationship between behavioral ability (latency to eat in the NSF test) and neuron survival rates, using the values obtained for each mouse in Fig 4B. Behavioral improvement was found to significantly correlate with the survival of newborn neurons (R 2 = 0.18 and p=0.0077), a result which supports a possible causal link between behavioral and neurobiological effects of ECS.
ECS continuation protocol linked to persistent behavioral and biological improvements
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To prevent the relapse observed after ECS treatment, we set up a continuation protocol and examined its effect on behavior and neuronal survival. Following the initial ECS treatment, mice were treated by a continuation protocol for 5 weeks, applying two active ECS sessions (ECS/ECS) or two sham treatments (ECS/sham) per week ( Figure 5A ). The NSF test was used 4 days after completing the protocol. The ECS/ECS protocol maintained the behavioral improvement (latency to eat 126±25 s, n=9) better than the ECS/sham treatment (latency 387±88 s, n=10) (unilateral MannWhitney test, p= 0.011, Figure 5B) . Notably, the latency to eat in MAP6 KO mice after ECS/ECS treatment was similar to that exhibited by ECS-treated mice at D10 and D17 ( Figure 4B ), whereas after ECS/sham treatment, the latency to eat was in the same range as that measured for ECStreated mice at D33 ( Figure 4B ).
To determine the effect of the continuation protocol on the survival of newborn neurons, two pools of proliferating neurons were labeled: neurons spontaneous proliferating 4 weeks before the end of the initial ECS treatment (EdU injection), and neurons proliferating at the end of the initial ECS treatment (BrdU) (timeline shown in Figure 5A ). On D40 after completing the initial ECS treatment, the number of EdU and BrdU cells in ECS/ECS-and ECS/sham-treated mice was determined for the whole hippocampus. The number of EdU-positive cells (neurons spontaneously born 9 weeks before counting) was not significantly different between ECS/ECS-and ECS/shamtreated mice ( Figure 5C ). In contrast, the number of BrdU-positive cells (neurons born 5 weeks before counting) was significantly higher in ECS/ECS-treated mice (1917±393 neurons, n=9) than in ECS/sham-treated mice (983±205 neurons, n=9) (unilateral Mann-Whitney test, p= 0.0252, Figure 5D ).
These results indicate that the ECS continuation protocol promoted the survival of newborn neurons produced during the initial ECS treatment, possibly enabling the persistence of behavioral improvement.
Discussion
In this study we used MAP6 KO mice, an animal model with constitutive hallmarks of psychiatriclike disorders to analyze the behavioral and long-range biological effects of ECS.
Proteomics analysis of brain or hippocampal protein content revealed no major detectable changes after ECS treatment. It might be of interest in future studies to determine the proteomic profile for more specific compartments, such as the synaptic compartment by working on synaptosomal preparations. By applying sub-fractioning it will be possible to analyze more than the tip of the iceberg and to quantify any changes in expression levels for non-major proteins. As no relevant specific biological pathway was identified by our proteomics analysis, we focused our study on the neurogenic effects of ECS. Indeed, adult hippocampal neurogenesis is known to be reduced in depressive conditions, both in animal models and in humans [25, 33, 34] , and experiments involving ablation of neuronal progenitors indicate that active neurogenesis is necessary for ECS to be effective [21, 25] .
Proliferation of neuronal progenitors is reported to be increased after ECS treatment in several animal models of depression [21, 35] , and ECS boosted their proliferation in our model. However, this proliferation increase might not be fully responsible for the rapid efficacy of ECS. Indeed, our results clearly demonstrate, for the first time, that ECS treatment efficiency most probably relies also on a direct and rapid increase in survival of hippocampal neurons, associated with an overall increase in synaptogenesis and synapse remodeling. Post-treatment, the newly-integrated neurons exhibit greater dendritic complexity and larger numbers of mushroom-type active dendritic spines, which allow better integration in existing neuronal networks. Based on these findings, we hypothesize that ECS enhances hippocampal and cortical neuronal connectivity and functions.
BDNF expression was also increased following ECS. Although the cellular pathways for adult hippocampal neurogenesis are currently not fully deciphered, a prominent role for BDNF and its signaling pathway may boost the integration and survival of newborn neurons, with a pivotal role in regulating spine density [36, 37] . Moreover, like Zhao et al. [38] , who showed increased spine M A N U S C R I P T
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19 density in mature hippocampal neurons in rats following ECS, dendritic spine density was also increased in mature cortical neurons in our model animals. Altogether, these results suggest a general increase in overall glutamatergic neuronal connectivity. Alterations to the Hypothalamic Pituitary Adrenal (HPA) axis have been reported in psychiatric disorders, in particular, it is known to be hyperactive in depressive conditions [39] . The HPA axis is negatively controlled by the hippocampus, thus the increased efficacy of hippocampal glutamatergic neurotransmission following ECS could tone down the hyperactivation of the HPA axis, producing improvements in depressive/anxiety symptoms. ECS-induced neurogenesis in brain areas involved in psychiatric disorders such as frontal areas and striatum may also account for the behavioral improvement observed [40, 41] .
In our model, like in humans [42, 43] , a behavioral relapse was observed several weeks after completing ECS treatment. Interestingly, this relapse was associated with the loss of recentlyintegrated neurons. Thus, ECS treatment does not increase the longevity of neurons. The behavioral relapse occurs even if the progenitor pool was enhanced during ECS treatment, indicating a failure to further integrate. In an attempt to maintain a higher integration rate for newborn neurons, we applied a continuation protocol similar to the highly beneficial protocol used in humans [43, 44] .
Two stimulations per week for 5 weeks following the initial ECS treatment were found to prevent relapse, with sustained survival of newborn neurons and associated behavioral improvements.
Overall, our data are compatible with the hypothesis that the initial ECS treatment favors proliferation of progenitors and promotes the survival of neurons born before ECS treatment, while continuation protocols allow the survival of neurons born during the initial ECS treatment.
These new findings allow us to propose a timeline for ECS action. The beneficial effect observed immediately after ECS treatment may mainly be due to increased survival and integration of spontaneously produced newborn neurons combined with a rapid increase in overall neuronal connectivity. The advantage of applying a continuation protocol is clear as behavioral defects are persistently alleviated, probably thanks to continued integration of new neurons. Compared to M A N U S C R I P T
20 pharmacological treatments, including antidepressants and antipsychotics known to enhance proliferation [45] [46] [47] [48] [49] , the more rapid effect of ECS is probably due to the enhanced integration of neurons, which is not triggered by drug treatments. The enhanced neuronal survival we observed in the neuroendocrine CORT model [6, 7] largely favors this hypothesis.
Our model should help to optimize the stimulation schedule over time with the objective of minimizing the number of sessions while maintaining an optimal level of behavioral improvement.
In particular it will be of interest to determine if the continuation treatment alone, without the acute treatment, is sufficient to obtain sustained behavioral effects.
Translation of the present results to humans is hampered by several limitations. The method by which ECS is administered in mice may produce biological and behavioral effects that are quite distinct from those induced by human ECT as current distribution might differ due to electrode placement and duration/intensity of stimulation. Also, in contrast to human studies, for each animal, we did not consider the seizure threshold so as to adapt the intensity of stimulation accordingly.
In clinical conditions, ECT is often administered to patients alongside pharmacological therapies, and continuation protocols associate ECT with a maximal antidepressant dose to prevent relapses [41] . Very few randomized studies have been published describing the combination of ECT and pharmacological treatments in humans [50] [51] [52] [53] [54] . This lack of data most probably stems from the difficulty of recruiting sufficiently large patient cohorts. The studies published mainly relate to venlafaxine, lithium or ketamine [50] [51] [52] [53] [54] . Thus, our mice model will be a nice tool to directly compare the capacity of several pharmacological molecules to potentiate ECT treatment, particularly during consolidation phases.
Our results suggest that ECS efficacy is linked to increased neuron survival associated with enhanced neuronal connectivity (increased spine density). Both these events can be considered as markers of alleviation of depressive-like behaviors. These preclinical bio-markers might be of interest when assaying the potential anti-depressive activity of any innovative neuro-active molecules. It will be of interest to assess the impact of epothilone D or Davunetive on these
biomarkers, as both molecules have been shown to alleviate several MAP6 behavioral deficits [11, [55] [56] [57] [58] .
Finally, within the context of the recent controversy surrounding the existence of adult neurogenesis in humans [59, 60] , the results presented here implicating neurogenesis in ECT's efficacy, associated with the observation of an increased hippocampal volume following ECT treatment in humans [61] , both support active neurogenesis in human hippocampus. Constitutive behavioral and biological defects of MAP6 KO mice respond to ECS treatment.
ECS efficacy relies on a high survival and integration rate of newborn neurons.
ECS continuation protocols efficacy depend on constant integration of adult neurons.
